NCT07113834View on ClinicalTrials.gov

Characteristics of Ankylosing Spondylitis Associated Uveitis

CompletedOBSERVATIONAL
Enrollment

22

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 1, 2023

Study Completion Date

August 1, 2024

Conditions
Uveitis
Interventions
DRUG

Adalimumab

A tumor necrosis factor-alpha (TNF-α) inhibitor used as a biologic agent for the treatment of ankylosing spondylitis. Administered subcutaneously as part of systemic immunomodulatory therapy.

DRUG

Systemic corticosteroids

Oral or intravenous corticosteroids (e.g., prednisolone) used to suppress systemic inflammation in cases of active AS or severe uveitis.

Trial Locations (1)

13111

Benha University, Banhā

All Listed Sponsors
lead

Benha University

OTHER

NCT07113834 - Characteristics of Ankylosing Spondylitis Associated Uveitis | Biotech Hunter | Biotech Hunter